Journal of the American Society of Nephrology : JASN

Journal of the American Society of Nephrology : JASN
Audio Summaries

Every issue of Journal of the American Society of Nephrology : JASN moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.

104 audio summariesNLM Catalog

Specialties

Journal of the American Society of Nephrology : JASN covers research in these specialties.

Recent summaries

The latest articles summarized from Journal of the American Society of Nephrology : JASN.

ZEB1-Mediated ATPAF1 Repression Impairs ATP Synthase Assembly and Promotes Tubular Epithelial Plasticity in CKD.

Nov 19, 2026

TGFβ-driven epithelial-mesenchymal transition in renal tubular cells is linked to impaired mitochondrial ATP synthase assembly, but whether profibrotic signaling directly causes this defect has been unclear. The authors show that TGFβ induces ZEB1 to repress ATPAF1, an ATP synthase assembly factor, reducing ATP production and promoting EMT, while restoring ATPAF1 or supplying ATP attenuates these changes. Consistent with this, ATPAF1 is reduced in injured tubules of fibrotic mouse kidneys and declines with disease severity in human CKD biopsies, and ATPAF1 delivery ameliorates fibrosis in mice, suggesting reduced ATP availability (rather than elevated membrane potential) as a driver of tubular plasticity.

Finerenone in Patients with Focal Segmental Glomerulosclerosis.

Nov 15, 2026

This prespecified analysis of the FIND-CKD trial asked whether finerenone, a mineralocorticoid receptor antagonist, slows kidney function decline and reduces proteinuria in people with nondiabetic CKD due to focal segmental glomerulosclerosis (FSGS). Among 215 participants with FSGS, finerenone slowed the eGFR decline by 1.3 mL/min/1.73 m²/year versus placebo, lowered urinary protein-to-creatinine ratio by 41% at 12 months, and was well tolerated with a similar rate of hyperkalemia-related events. Although the kidney composite outcome was not statistically significant (HR 0.58, 95% CI 0.30–1.15), these exploratory findings suggest finerenone may be a promising therapy for FSGS warranting confirmation in dedicated trials.

Endoplasmic Reticulum Membrane Insertion of APOL1 Risk Alleles Disrupts Calcium Homeostasis and Is Mitigated by Autophagic Clearance​.

Nov 13, 2026

APOL1 risk variants (G1 and G2) are a major cause of kidney disease in people of African ancestry, but how they interact with intracellular membranes and are cleared by the cell was unclear. This study asked whether risk alleles insert more into the endoplasmic reticulum (ER) membrane, deplete ER calcium, and are cleared by autophagy, using split-GFP topology assays, ER calcium indicators, and transgenic Drosophila nephrocytes. The authors found that G1 and G2 insert more readily into the ER membrane than G0, causing greater ER calcium depletion, and that autophagy (but not proteasome) clears APOL1; rapamycin reduced APOL1 levels and rescued cell viability and nephrocyte dysfunction in vivo.

Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN.

Nov 13, 2026

This open-label extension of the VALIANT phase 3 trial asked whether the proteinuria reduction and kidney function stability seen with pegcetacoplan (a C3/C3b inhibitor) at 26 weeks persist through 52 weeks in patients with C3 glomerulopathy or primary immune-complex MPGN. Participants who received pegcetacoplan throughout maintained about a 67% reduction in proteinuria at week 52 with stable eGFR (-3.7 mL/min/1.73 m² change, not statistically significant), while those switched from placebo showed proteinuria reduction and eGFR stabilization after starting treatment. No new safety signals, encapsulated meningococcal infections, deaths, or allograft losses were reported, supporting sustained one-year benefit and an acceptable safety profile.

Association of Second Anti-hypertensive Agent with Outcomes in People with CKD on ACEi/ARB Therapy.

Nov 13, 2026

This target trial emulation using Veterans Health Administration data asked which second antihypertensive added to ACEi/ARB therapy is linked to better outcomes in people with non-dialysis CKD, since guidelines are silent on this choice. Among 150,369 patients, adding a thiazide diuretic was associated with lower risks of cardiovascular events, death, and kidney outcomes than adding a calcium channel blocker, β-blocker, or loop diuretic. These observational findings suggest thiazides may be a preferred add-on, though residual confounding is possible.

Implementation Strategies to Improve CKD Testing and Delivery of Guideline-Directed Medical Therapy: A Scoping Review.

Nov 12, 2026

This scoping review asked which implementation strategies effectively improve CKD testing (eGFR and UACR) and prescribing of guideline-directed medical therapies across 24 controlled studies. Patient-directed home testing and automated laboratory ordering with clinical decision support increased testing, but this rarely led to more CKD diagnoses or GDMT prescriptions. Only 5 of 17 treatment-focused studies increased GDMT prescribing, and all of these used longitudinal, team-based approaches (e.g., pharmacist- or APP-led management, nephrologist-supported care, or proactive registry outreach) rather than passive, single-touch tactics like isolated alerts.

Pathogenic Gd-IgA1: Redefining the Role of Galactose-Deficient IgA1 in IgA Nephropathy.

Nov 9, 2026

This review proposes the concept of "pathogenic Gd-IgA1," a disease-relevant subset of circulating galactose-deficient IgA1 that may drive glomerular inflammation in IgA nephropathy, rather than the entire circulating pool. The authors ask whether longitudinal changes in serum Gd-IgA1 and proteinuria from recent therapeutic trials suggest that only certain Gd-IgA1 molecules are pathogenic. They outline three candidate features of this subset: a mucosal origin, molecular properties favoring selective mesangial deposition, and the ability to form immune complexes that activate complement.

Interorgan Signaling in Kidney Health and Disease.

Oct 28, 2026

This review examines how the kidney communicates with distant organs through hemodynamic, endocrine, metabolic, immune, neural, and microbial pathways, and how these signals contribute to systemic health and disease. The authors ask how kidney-organ crosstalk can be understood mechanistically rather than described only in broad associative terms, emphasizing experimentally supported mediators and causal models. They also identify limitations of current methods (global genetic manipulation, indirect signal measures, isolated organ-pair studies) and propose that emerging technologies could clarify signal origins, routes, and consequences to enable biomarker discovery and kidney therapies with fewer off-target effects.

Association of Medicare's ESRD Treatment Choices Model with Timely Access to Kidney Transplantation in the Southeastern United States.

Oct 28, 2026

This study examined whether Medicare's ESRD Treatment Choices (ETC) Model, which gave financial incentives to a randomly selected 30% of dialysis facilities, improved upstream transplant access steps such as referral, evaluation, and waitlisting. Using difference-in-differences analyses of over 26,000 Traditional Medicare patients starting dialysis in Georgia, North Carolina, and South Carolina, the authors found point estimates suggesting increases in timely referral (3.58 points), evaluation initiation (8.52 points), and waitlisting or living-donor transplant (3.61 points), but all confidence intervals included zero. They concluded that ETC implementation did not produce statistically definitive improvements in transplant access, suggesting that facility incentive misalignment alone may not explain the model's limited impact.

Proteinuria, eGFR Decline, and the Pathway to Kidney Failure in Alport Syndrome.

Oct 28, 2026

This review asks how proteinuria and eGFR decline relate to progression toward kidney failure in Alport syndrome, and which measures best serve as clinical trial endpoints. The authors propose that proteinuria reflects early disease processes, with a partly reversible podocyte foot-process effacement component and a less reversible component tied to podocyte loss and glomerulosclerosis, while eGFR decline reflects later cumulative nephron loss. They conclude that biopsy markers are currently most useful for confirming target engagement, and that an endpoint framework should account for genotype, sex, age, baseline measures, and nonlinear disease trajectories.

Listen to Journal of the American Society of Nephrology : JASN

14-day free trial. Every new article, summarized in ~3 minutes.